title: [Value of galvanotherapy for localised prostate cancer].
abstract: In recent years electrotherapy has become an accepted treatment option in several medical subfields such as defibrillation during cardiopulmonary resuscitation, electroconvulsive shock treatment (ECT) in conjunction with antidepressant therapy, pain management and physical therapy [transcutaneous electrical nerve stimulation (TENS), diathermia, Stanger bath therapy, etc.]. In recent years several groups, especially from Asia, have investigated the therapeutic effect of electricity in the treatment of malignant tumours. They determined basic principles of electrotherapy and developed different theories of tumour destruction. They postulated a multifactorial tissue effect of continuous current based on tumour cell necrosis due to pH shifting and alteration of membrane potential. In clinical trials similar oncological results of electrotherapy in several malignant tumours compared to established therapeutic methods were observed, whereas clinical trial designs to some extent were not consistent with internationally accepted scientific standards. Regarding electrotherapy of localised prostate cancer only limited data with a few cases and controversial study designs were published. According to EAU guidelines electrotherapy of localised prostate cancer as an alternative treatment option is not recommended and is still an experimental method. For this procedure well-designed clinical trials and a longer follow-up are mandatory to assess the true role of electrotherapy in the management of prostate cancer.
authors.affiliation: Klinik für Urologie, Heinrich-Heine-Universität, Moorenstrasse 5, 40225 Düsseldorf. christian.arsov@med.uni-duesseldorf.de
authors.forename: C
authors.initials: C
authors.lastname: Arsov
authors.forename: C
authors.initials: C
authors.lastname: Winter
authors.forename: P
authors.initials: P
authors.lastname: Albers
mesh_terms: D004599:Electric Stimulation Therapy / Q000379:methods* / Q000639:trends*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy*